about
Comparability of a three-dimensional structure in biopharmaceuticals using spectroscopic methods.Validation of three viable-cell counting methods: Manual, semi-automated, and automatedProduction of recombinant proteins in E. coli by the heat inducible expression system based on the phage lambda pL and/or pR promoters.New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept.Assessment of physicochemical properties of rituximab related to its immunomodulatory activity.Physicochemical and biological characterization of a biosimilar trastuzumab.Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization.Process signatures in glatiramer acetate synthesis: structural and functional relationships.Analysis of recombinant monoclonal antibodies by capillary zone electrophoresis.Kinetics and conformational stability studies of recombinant leucine aminopeptidase.Design of a strong cation exchange methodology for the evaluation of charge heterogeneity in glatiramer acetate.The phosphorelay signal transduction system in Candida glabrata: an in silico analysis.Extensive preclinical evaluation of an infliximab biosimilar candidate.Optimization of a recombinant human growth hormone purification process using quality by design.Capillary Electrophoresis Separation of Monoclonal Antibody Isoforms Using a Neutral Capillary.Response to: Comment on "New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept".Nanoparticles for Protein Sensing in Primary Containers: Interaction Analysis and Application.Interferon-alpha 2b quantification in inclusion bodies using reversed phase-ultra performance liquid chromatography (RP-UPLC).Analysis of therapeutic proteins and peptides using multiangle light scattering coupled to ultra high performance liquid chromatographyTheoretical approximations and experimental extinction coefficients of biopharmaceuticalsBiofilm characterization of Fusarium solani keratitis isolate: increased resistance to antifungals and UV light
P50
Q30363975-729EFBC5-F3FB-4498-B80D-89DF44BEC24DQ33782954-1FB89295-FBF5-43AA-B9B4-543B5189B102Q37713994-E5416CD0-92D6-45E4-A86B-7531DE83949CQ38759624-C0227620-2215-413F-AC0A-9F0925754CB4Q38875063-4A52B95D-5024-46B5-9075-BAF5A412C5DDQ41443472-A32EBB96-5863-4CB9-9631-913106696CC8Q42000964-56303094-CBC0-435B-8799-0FC076F3E2ADQ42362266-85FBF053-3A32-4284-859A-04654C486651Q43720382-D6CAA9CC-D022-4163-9547-024501396D1DQ44864214-32F5FB92-7EBB-475B-877F-F0CF19B7D9EFQ46480044-F48B4BB3-4EAD-4EAF-9AB4-03DE64B7E1C5Q47284767-5DACC800-15AA-4ED5-B1D9-A409C943B49CQ48832842-BE433FC4-66B8-4ED3-B9AE-8BEFB5C90DFEQ50885168-DD05988A-0BC9-4A47-B557-EC8834EBEC27Q51171604-D4790BDF-766F-4EC2-9FA7-8B632441EC96Q52575013-57DA3883-2AD0-45F4-B881-A4C1DFC94E56Q52665454-A9890C2E-724E-4F70-900E-1A65BDF646ABQ54388818-765768FA-D87E-4899-A33A-AE35DB09EF7FQ86846916-33B2EA7D-24D2-4A43-84DC-EC2AD65FA75AQ86991977-0703E7F4-400F-42DD-B84A-02AFDDC4BBDDQ92330619-4B8B97AA-B617-424E-8D53-3585882DE323
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Néstor O Pérez
@es
Néstor O Pérez
@nl
Néstor O Pérez
@sl
Néstor O. Pérez
@en
type
label
Néstor O Pérez
@es
Néstor O Pérez
@nl
Néstor O Pérez
@sl
Néstor O. Pérez
@en
prefLabel
Néstor O Pérez
@es
Néstor O Pérez
@nl
Néstor O Pérez
@sl
Néstor O. Pérez
@en
P106
P1153
6507275892
P21
P31
P496
0000-0002-4043-1097